Theracryf Plc
TCF.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | £0 | £396 | £442 | £0 |
| % Growth | -100% | -10.4% | – | – |
| Cost of Goods Sold | £2,112 | £11 | £13 | £16 |
| Gross Profit | -£2,112 | £385 | £429 | -£16 |
| % Margin | – | 97.2% | 97.1% | – |
| R&D Expenses | £398 | £2,770 | £4,720 | £2,599 |
| G&A Expenses | £0 | £1,160 | £765 | £564 |
| SG&A Expenses | £12 | £1,160 | £779 | £576 |
| Sales & Mktg Exp. | £0 | £0 | £14 | £12 |
| Other Operating Expenses | -£398 | £15 | £0 | £0 |
| Operating Expenses | £12 | £3,945 | £5,499 | £3,175 |
| Operating Income | -£2,124 | -£3,560 | -£5,070 | -£3,191 |
| % Margin | – | -899% | -1,147.1% | – |
| Other Income/Exp. Net | £39 | -£6 | £98 | £22 |
| Pre-Tax Income | -£2,085 | -£3,566 | -£5,006 | -£3,169 |
| Tax Expense | £144 | -£429 | -£963 | -£439 |
| Net Income | -£1,941 | -£3,137 | -£4,043 | -£2,730 |
| % Margin | – | -792.2% | -914.7% | – |
| EPS | -0.004 | -0.011 | -0.015 | -0.01 |
| % Growth | 68.4% | 22.4% | -48.5% | – |
| EPS Diluted | -0.004 | -0.011 | -0.015 | -0.01 |
| Weighted Avg Shares Out | 538,419 | 274,888 | 274,888 | 274,888 |
| Weighted Avg Shares Out Dil | 538,311 | 274,888 | 274,888 | 274,888 |
| Supplemental Information | – | – | – | – |
| Interest Income | £5 | £0 | £98 | £24 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £69 | £11 | £13 | £16 |
| EBITDA | -£2,055 | -£3,549 | -£4,993 | -£3,153 |
| % Margin | – | -896.2% | -1,129.6% | – |